Committee on Veterans' Affairs. Ordered to be reported with an amendment in the nature of a substitute favorably.
This bill amends the VA’s Precision Medicine for Veterans Initiative to emphasize brain and mental health conditions, including repetitive low‑level blast exposure and dementia. It requires a VA–DoD data‑sharing partnership, mandates specific research projects (big‑data assessments, implementation studies, translational growth hormone therapy study, and quality improvement studies), directs National Academies assistance and biennial reporting, and authorizes $5 million annually for fiscal years 2025–2034.
Growth hormone translational study seen as speculative versus promising
Relative to its intended legislative type, this bill modifies an existing VA precision medicine initiative to broaden its subject matter, require multiple specific research activities (including big-data assessments, implementation and quality-improvement studies, and a translational trial), establish a DoD–VA data-sharing partnership, engage the National Academies, require recurring reporting and assessment, and authorize appropriations of $5 million annually for 2025–2034.
This bill amends the VA’s Precision Medicine for Veterans Initiative to emphasize brain and mental health conditions, including repetitive low‑level blast exposure and dementia.
It requires a VA–DoD data‑sharing partnership, mandates specific research projects (big‑data assessments, implementation studies, translational growth hormone therapy study, and quality improvement studies), directs National Academies assistance and biennial reporting, and authorizes $5 million annually for fiscal years 2025–2034.
Modest cost, veterans-health focus, and National Academies involvement increase viability; success still depends on appropriations, DoD cooperation, and avoiding procedural blocks.
Relative to its intended legislative type, this bill modifies an existing VA precision medicine initiative to broaden its subject matter, require multiple specific research activities (including big-data assessments, implementation and quality-improvement studies, and a translational trial), establish a DoD–VA data-sharing partnership, engage the National Academies, require recurring reporting and assessment, and authorize appropriations of $5 million annually for 2025–2034.
Growth hormone translational study seen as speculative versus promising
These are examples from the analysis, not a ranked list of the most-affected groups.
Growth hormone translational study seen as speculative versus promising
Likely broadly supportive because it expands research into veterans’ brain health and coordinates VA and DoD data.
Concerned the funding level is modest and that the growth hormone translational study is speculative; will demand strong safety, transparency, and equity protections.
Pragmatic support for evidence‑driven veteran health research and interagency data sharing, paired with caution about implementation details and costs.
Will seek clear metrics, data‑security assurances, and phased evaluation before wider rollouts.
Generally supportive of targeted veterans research but wary of federal overreach, data sharing that could compromise military operations, and spending for unproven therapies.
Would favor tighter security, fiscal restraint, and stronger evidence requirements.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Modest cost, veterans-health focus, and National Academies involvement increase viability; success still depends on appropriations, DoD cooperation, and avoiding procedural blocks.
The bill has not accumulated any surfaced votes yet.
Growth hormone translational study seen as speculative versus promising
Modest cost, veterans-health focus, and National Academies involvement increase viability; success still depends on appropriations, DoD coo…
Relative to its intended legislative type, this bill modifies an existing VA precision medicine initiative to broaden its subject matter, require multiple specific research activities (including big-data assessments, im…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.